GI Dynamics Announces Agreement With CMS Medical for Distribution of EndoBarrier® Therapy in Brazil
Published: Mar 06, 2013
LEXINGTON, Mass. & SYDNEY & GOIÂNIA, Brazil--(BUSINESS WIRE)--GI Dynamics, Inc. (ASX: GID) today announced that it has entered into an agreement with CMS Medical (CMS), headquartered in Goiânia, Brazil, to distribute its lead product, EndoBarrier®, a breakthrough therapy for type 2 diabetes and/or obesity. Under the agreement, CMS will be the exclusive distributor of EndoBarrier Therapy in Brazil, following regulatory approval of the product in that country.